In research settings AOD-9604 was studied mainly as a subcutaneous injection, with the developer, Metabolic Pharmaceuticals, also pursuing an oral formulation as a central commercial aim and exploring transdermal delivery as a further option. The honest bottom line comes first: no approved, regulator-sanctioned dosing protocol exists, because the compound was never approved and its development was halted after trials did not show the hoped-for weight-loss efficacy. Any dosing figures now circulating on vendor pages, forums, or gray-market sources are extrapolations and unofficial lore rather than a validated medical standard.
AOD-9604 was administered mainly by subcutaneous injection at defined daily milligram doses in supervised trials, but development was halted for lack of efficacy and no approved human dosing protocol exists.
Three delivery routes appear in the AOD-9604 research record, and they were not pursued equally. Subcutaneous injection was the workhorse of the dose-ranging work, while the developer invested real money in an oral formulation as a headline commercial proposition, and transdermal delivery was explored as a further avenue. Bioavailability drove why route choice mattered: an injected peptide delivers a reliable fraction of the dose to the bloodstream, whereas oral peptides are largely broken down by stomach acid before they can absorb.
The AOD-9604 research record documents three delivery routes - subcutaneous injection as the primary experimental route, an oral formulation as the developer's chief commercial aim, and transdermal delivery as an exploratory option.
Subcutaneous injection led the early work for a practical pharmacological reason: it sidesteps the digestive system entirely. Swallowed peptides meet stomach acid and proteolytic enzymes that break the molecule apart before absorption, so oral exposure runs low and erratic, whereas placing the compound in the fatty tissue under the skin produces a steady, well-characterized exposure curve. That predictability is what a dose-finding study depends on.
Subcutaneous injection was the primary early route because it bypasses digestive degradation and delivers a predictable, repeatable exposure, the precondition a dose-finding study requires to link dose to effect.
The oral formulation mattered mostly for what it promised commercially. AOD-9604 was developed as an anti-obesity candidate for a broad consumer population, and for that audience a daily injection is a hard sell while a capsule is familiar, so an effective oral form would have set the product apart from peptides that can only be injected. The catch is the science: peptides are fragile in the gut, and pursuing an oral version meant taking on that absorption problem directly.
| Dimension | Oral formulation | Injectable form |
|---|---|---|
| Market appeal | High - a familiar capsule for a broad consumer audience | Lower - a daily injection is a harder sell |
| Bioavailability | Poor - degraded by gut acid and enzymes | Reliable - direct delivery to the bloodstream |
| Formulation difficulty | High - must overcome intestinal breakdown | Low - an established, straightforward route |
The oral formulation's significance was commercial - a swallowable anti-obesity product would have outsold an injectable - but it required solving the poor gut absorption that limits nearly all oral peptides.
Clinical evaluation of AOD-9604 used defined daily milligram amounts given under medical supervision, structured as dose-ranging studies that compared several fixed daily levels against each other and against placebo. Expressing a dose as a milligram quantity per day is standard trial practice, because it ties any observed effect, or its absence, to a precise level of exposure. The supervised setting mattered as much as the number: participants received the compound within a monitored protocol with defined eligibility and safety reporting.
The trials tested defined daily milligram doses in a supervised dose-ranging design against placebo, but because AOD-9604 was never approved those levels never became an authorized human dosing schedule.
AOD-9604 clears from circulation relatively quickly, and a short half-life directly shapes how a dosing schedule is designed. Half-life is the time it takes for roughly half of the compound present to be eliminated, so a short one means levels rise after a dose and then fall away within a brief window rather than lingering for days. Maintaining a useful concentration therefore generally calls for dosing at least daily, and the trial schedules reflected that rhythm.
Because AOD-9604 has a short circulating half-life, blood levels fall within a brief window after each dose, so trial schedules relied on at-least-daily administration to sustain exposure.
An officially sanctioned dosing protocol exists only once a compound clears the full regulatory pathway, where a regulator reviews the trial evidence and formally endorses a specific dose for a specific approved use. AOD-9604 never reached that point: its development as an anti-obesity therapeutic was halted after the clinical program failed to show the weight-loss efficacy it was chasing. Because the program stopped short, the dosing question was never settled by any authority, so there is no approved indication and therefore no approved dose.
No approved dosing protocol exists because AOD-9604 never cleared regulatory approval, its development having been halted for lack of efficacy, so any figure presented online as a standard dose asserts a legitimacy no authority ever granted.
The dosing figures on vendor pages and discussion forums should be read as unreliable, because of where they come from rather than how they are phrased. Many are extrapolations pieced together from fragments of the research record and then repeated until repetition lends a false air of authority, while others are simply vendor lore attached to a research chemical with no independent verification. The gray-market supply chain deepens the problem: material sold outside an approved channel carries no guarantee of labeled quantity, purity, or even identity.
| Dimension | Documented trial dosing | Circulating vendor/forum figures |
|---|---|---|
| Source | Defined within a controlled study | Extrapolation and repeated vendor lore |
| Verification | Supervised, tied to a specific protocol | None independent of the seller |
| Product certainty | Known compound and quantity | Gray-market: quantity, purity, and identity unverified |
The dosing figures circulating on vendor and forum sites are extrapolations and unverified lore attached to gray-market material of unguaranteed purity and identity, not a validated standard derived from the supervised trial record.
As a matter of chemistry, injectable peptides like AOD-9604 are usually supplied as a lyophilized, or freeze-dried, powder, because a dry peptide is far more stable in storage than one held in solution. Reconstitution refers to dissolving that powder in a sterile liquid before it can be drawn up, a handling step common to lyophilized peptides across the field. These details are offered as neutral background on how a research-grade peptide is stored and prepared, under a research-chemical label rather than as an approved medicine.
Injectable AOD-9604 is documented as a lyophilized powder reconstituted in sterile liquid and kept cold to limit degradation, handled and sold under a research-chemical label rather than as an approved medicine.
Educational use only. This article describes what the published scientific and clinical literature reports about AOD-9604. It is not medical advice, and it does not recommend, prescribe, or tell anyone to use anything described here. The regulatory status shown at the top of this page reflects what the record showed on the date given there and can change. mdpep.com does not sell any substance described here, does not endorse human use of it, and does not direct anyone to obtain it.
This is not guidance for your situation. Nothing here accounts for your medical history, your current medications, or anything else specific to you, and none of it should be used to make a decision about your own health.
Affiliate disclosure. Some links on this site are affiliate links, and mdpep.com may earn a commission when they are used. That never affects what is written here, it is not an endorsement of any vendor, and it is not a statement that anything described on this page is available to buy.
Every claim here ties to a named primary source and a date, written as plain documentation with nothing for sale. That is how MD PEP covers the whole peptide market.
